Activating the patient’s immune system against their personal cancer antigens
Using GenVivo’s proprietary gene delivery technology, we create off-the-shelf immunotherapies, that are delivered intravenously, to mount a targeted attack against solid tumors.
We are a clinical stage company with breakthrough vector-based platforms for immunotherapeutics in oncology
We are committed to enhancing the overall patient treatment experience.
Creating innovative treatment options
Innovative vector-based genetic medicine platform for oncology targets
Our proprietary platform aims to set new standards in safety, efficacy, specificity of target and flexibility in mRNA payloads.
Be part of the
Our philosophy is to provide growth
opportunities and a comprehensive
compensation and benefits package to
support our most valued assets, our